Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3b randomized multicentre, open-label trial assessing efficacy, safety, and tolerability of switching from oral antiretroviral therapy (ART) to LA

Next Previous
Trial Profile

A phase 3b randomized multicentre, open-label trial assessing efficacy, safety, and tolerability of switching from oral antiretroviral therapy (ART) to LA

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir+rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms CaReS

Most Recent Events

  • 19 Apr 2024 New trial record
  • 06 Mar 2024 Results at 48 weeks presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top